Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 MAD Study of ID110521156 in Healthy Subjects
NCT06635226Phase 1Recruiting
- Sponsor
- Ildong Pharmaceutical Co Ltd
- Start
- Nov 2024
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ID110521156 in type 2 diabetes mellitus (T2DM) and obesity (3 cohorts), sponsored by Ildong Pharmaceutical Co Ltd. Primary endpoint: Adverse Events and Serious Adverse Events up to 47 days. Started Nov 2024; status: recruiting.
02
Drugs
ID110521156
03
Conditions
type 2 diabetes mellitus (T2DM)obesity
Beyond the preview
Go deeper on NCT06635226.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06635226.